Immunovant’s plans for autoimmune asset; Wall Street worries about Moderna’s RSV candidate

Plus, news about Novo Holdings, Gritstone Bio, Invivyd and Science 37:

Immunovant outlines big plans for its autoimmune program: The biotech now expects to launch four to five “potentially registrational” trials for IMVT-1402 by March 2025 and studies in up to 10 indications by March 2026. Immunovant touted the asset’s “best-in-class” potential after a Phase I study in healthy volunteers read out positively last November. — Max Gelman

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Conversion Practices Tied to Greater Symptoms of PTSD, Suicidality

Exposure to conversion practices was associated with increases in several mental health symptoms for sexual and gender minority individuals, according to a cross-sectional study. The

October 1, 2024

Co-bots and automatons: the divergent futures of robotics – Pharmaceutical Technology

Robots are used across industries, like this cleaning robot in Hangzhou. Photo: Costfoto/NurPhoto via Getty Images. Robotics is a surprisingly old discipline, arguably beginning in

October 10, 2023

OCEANIC-AF Trial Sunk; Second Renal Denervation Device Approved; Strep-Stroke Link?

Bayer announced that the phase III OCEANIC-AF study of the oral factor XIa inhibitor asundexian was stopped early due to inferior efficacy compared with apixaban

November 22, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.